

Application No. 09/836,627	Applicant(s) SCOTT ET AL.	
Examiner Humera N. Sheikh	Art Unit 1615	

Status of Application: Allowed

(3) _____.

(4) _____.

Time: 4pm (EST)

☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

If Yes, provide a brief description:

none

See Continuation Sheet

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Examiner requested and received source/manufacture information from Applicant's representative regarding the following tradenames/trademarks: (1) Eudragit® S100; (2) Eudragit® L100; (3) Claversal® and (4) Salofalk®. These trademarks/tradenames are listed in the specification on page 2, lines 10-13. Applicant indicated that (1) Eudragit® S100/L100 are available from Roehm GmbH, Darmstadt, Germany (also see U.S. Patent No. 6,228,396) regarding source/manufacture of Eudragit® forms; (2) Claversal® is available from GlaxoSmithKline, Madrid, Spain; (3) Salofalk® - available by Dr. Falk Pharma, GmbH, Freiburg, Germany. Examiner requested and received approval from Applicant's representative to incorporate the trademark/tradename information through an Examiner's Amendment. A Notice of Allowability will soon be issued.